MUSK and myasthenia gravis: Our ‘five new things’ include thymectomy, new immunotherapies, recent guidelines, progress in biomarkers, and the concept of MG ‘age’ and ‘stage’, and restricting ourselves to acetylcholine receptor (AChR) antibody-positive and muscle-specific kinase (MuSK) antibody-positive patients.